PRESS RELEASE published on 05/12/2025 at 18:00, 10 months 11 days ago Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC Oxurion NV received transparency notifications regarding changes in shareholding percentages from Atlas Special Opportunities II, LLC. The biopharmaceutical company is focused on developing ophthalmic therapies for retinal disease Biopharmaceutical Shareholding Changes Ophthalmic Therapies Oxurion NV Transparency Notifications
PRESS RELEASE published on 05/12/2025 at 18:00, 10 months 11 days ago Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC Oxurion NV ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC over aandelentransacties en voldoet aan Belgische transparantiewetgeving. Het biofarmaceutisch bedrijf ontwikkelt oftalmologische therapieën Transparantiekennisgevingen Oxurion NV Oftalmologische Therapieën Belgische Transparantiewetgeving Biofarmaceutisch Bedrijf
BRIEF published on 05/09/2025 at 18:05, 10 months 14 days ago Oxurion Increases Capital Following Convertible Bond Conversion Convertible Bonds Capital Increase Atlas Special Opportunities Vision Preservation Oxurion Shares
BRIEF published on 05/09/2025 at 18:05, 10 months 14 days ago Oxurion augmente son capital suite à la conversion d'obligations convertibles Obligations Convertibles Augmentation De Capital Opportunités Spéciales Atlas Préservation De La Vision Actions Oxurion
PRESS RELEASE published on 05/09/2025 at 18:00, 10 months 14 days ago Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC converts 4 convertible bonds in Oxurion, resulting in EUR 100,000 capital increase, supporting innovative therapeutics development for vision preservation in elderly. Oxurion shares update post-capital increase Capital Increase Oxurion Atlas Special Opportunities, LLC Innovative Therapeutics Vision Preservation
PRESS RELEASE published on 05/09/2025 at 18:00, 10 months 14 days ago Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie Atlas Special Opportunities, LLC converteert 4 obligaties in Oxurion, resulterend in EUR 100.000 kapitaalverhoging. Oxurion verstrekt 1.521.372 gewone aandelen. Meer info op www.oxurion.com Kapitaalverhoging Atlas Special Opportunities Aandelen Oxurion Innovatieve Geneesmiddelen
BRIEF published on 04/25/2025 at 18:35, 10 months 28 days ago Oxurion Arrête une Transaction de 2024 et Continue les Négociations pour une Nouvelle Acquisition Acquisition Négociations CRO Oxurion Biométrie
BRIEF published on 04/25/2025 at 18:35, 10 months 28 days ago Oxurion Stops 2024 Transaction and Continues Negotiations for New Acquisition Acquisition Negotiations CRO Oxurion Biometrics
PRESS RELEASE published on 04/25/2025 at 18:30, 10 months 28 days ago Oxurion kondigt stopzetting aan van de transactie van juli 2024 en bevestigt de voortzetting van de gesprekken over het overnameproject aangekondigd in maart 2025 Oxurion NV (Euronext Brussels: OXUR) stops negotiations for majority stake acquisition in French CRO, continues talks for majority stake in CRO specializing in biometrics and advanced data management. Market updates to follow Majority Stake Acquisition Clinical Studies CRO Oxurion NV Biometrics
PRESS RELEASE published on 04/25/2025 at 18:30, 10 months 28 days ago Oxurion announces that the transaction of July 2024 is stopped and confirms continuation of discussions regarding the acquisition project announced in March 2025 Oxurion NV halts acquisition of French CRO, pursues deal with biometrics CRO to expand capabilities in clinical data management. Progress updates to follow Acquisition CRO Oxurion NV Clinical Data Management Biometrics
Published on 03/23/2026 at 14:05, 6 hours 22 minutes ago Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Published on 03/23/2026 at 14:00, 6 hours 27 minutes ago BlackBerry AtHoc Advances Command Center for Faster Response and Tighter Control During Critical Operations
Published on 03/23/2026 at 13:05, 7 hours 22 minutes ago SouthGobi Announces Disclosable and Connected Transaction Deferral of Payment Obligations Under Convertible Debenture and Amended and Restated Cooperation Agreement
Published on 03/23/2026 at 12:32, 7 hours 55 minutes ago Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%
Published on 03/23/2026 at 12:30, 7 hours 57 minutes ago Digi Power X to Announce 2025 Year End Financial Results on March 31st
Published on 03/23/2026 at 19:30, 56 minutes ago Habitat for Humanity launches Let's Open the Door campaign to drive awareness of global housing need
Published on 03/23/2026 at 19:00, 1 hour 27 minutes ago PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 16 MARS 2026 au 20 MARS 2026
Published on 03/23/2026 at 18:15, 2 hours 11 minutes ago ISX Financial EU Plc Announces Corporate Name Change to Xryma Plc
Published on 03/23/2026 at 18:09, 2 hours 18 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/23/2026 at 19:08, 1 hour 19 minutes ago Reporting on share buyback transactions carried out between March 16 and March 20, 2026
Published on 03/23/2026 at 19:08, 1 hour 19 minutes ago Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 16 et le 20 mars 2026
Published on 03/23/2026 at 18:37, 1 hour 49 minutes ago ALTAREA : Déclaration d’opérations sur actions propres
Published on 03/23/2026 at 17:45, 2 hours 42 minutes ago ENGIE will build, own and operate its largest onshore wind farm worldwide in Egypt
Published on 03/23/2026 at 17:45, 2 hours 42 minutes ago En Égypte, ENGIE va construire et exploiter son plus grand parc éolien terrestre au monde